Evidence map›Paper›PMID 30240496›Full record

ArticleAngewandte Chemie (International ed. in English)2018

Design of a Multicompartment Hydrogel that Facilitates Time-Resolved Delivery of Combination Therapy and Synergized Killing of Glioblastoma.

Poulami Majumder, Ulrich Baxa, Scott T R Walsh, Joel P Schneider

Abstract read
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
6.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 104 citations in OpenAlex.

  1. A multidomain peptide hydrogel-liposome composite for controlled release of a cyclic dinucleotide in oral cancer.Journal of controlled release : official journal of the Controlled Release Society · 2026
    Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Peptide hydrogels for affinity-controlled release of therapeutic cargo: Current and potential strategies.Journal of peptide science : an official publication of the European Peptide Society · 2022
    Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Poulami MajumderChemical Biology Laboratory, National Cancer Institute, 376 Boyles St, Frederick, MD, 21702, USA.ORCID 0000-0002-8201-0039
Ulrich BaxaNational Cryo-Electron Microscopy facility, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA.
Scott T R WalshChemical Biology Laboratory, National Cancer Institute, 376 Boyles St, Frederick, MD, 21702, USA.
Joel P SchneiderChemical Biology Laboratory, National Cancer Institute, 376 Boyles St, Frederick, MD, 21702, USA.ORCID 0000-0002-4403-7900
Frederick National Laboratory for Cancer Research · US

Funding

Design and Utility of Novel Protienaceous BiomaterialsZIABC011313 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI SCHNEIDER, JOEL · 2010 to 2025
$19.0M
Development of antibacterial agents and materialsZIABC011314 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI SCHNEIDER, JOEL · 2010 to 2025
$8.9M
Intramural NIH HHS ZIA BC011313Intramural NIH HHS ZIA BC011314NCI NIH HHS 1 ZIABC01131308
6 · The paper itself

Abstract

There is significant current interest in identifying new combination therapies that synergize to treat disease, and it is becoming increasingly clear that the temporal resolution of their administration greatly impacts efficacy. To facilitate effective delivery, a multicompartment hydrogel material was developed that is composed of spherical vesicles interlaced within a self-assembled peptide-based network of physically crosslinked fibrils that allows time-resolved independent co-delivery of small molecules. This material architecture effectively delivers the EGFR kinase inhibitor Erlotinib (ERL) and Doxorubicin (DOX, DNA intercalator) in an ERL→DOX sequential manner to synergistically kill glioblastoma, the most aggressive form of brain cancer.

Indexed as

Antineoplastic AgentsApoptosisBrain NeoplasmsCell Line, TumorDoxorubicinDrug CarriersDrug Delivery SystemsDrug SynergismErlotinib HydrochlorideGlioblastomaHumansHydrogelsPeptidesProtein Kinase InhibitorsAntineoplastic AgentsDoxorubicinDrug CarriersErlotinib HydrochlorideHydrogelsPeptidesProtein Kinase Inhibitorscombination therapydoxorubicinhydrogelspeptidesself-assembly

Identifiers

PMID30240496
PMCPMC6424348
OpenAlexW2894527492

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.